Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tetrazoles/adverse effects"'
Autor:
Jes Olesen, Katrine Falkenberg
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-5 (2018)
Falkenberg, K & Olesen, J 2018, ' Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers ', The Journal of Headache and Pain, vol. 19, 71 . https://doi.org/10.1186/s10194-018-0890-y
The Journal of Headache and Pain
Falkenberg, K & Olesen, J 2018, ' Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers ', The Journal of Headache and Pain, vol. 19, 71 . https://doi.org/10.1186/s10194-018-0890-y
The Journal of Headache and Pain
Background Previous studies indicate that sumatriptan is not effective when second messenger levels are high as after cilostazol provocation. Therefore, we have conducted the present study, where sumatriptan is administrated as pretreatment before cA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2264796fa41e9dee44a198d4e44b91
http://link.springer.com/article/10.1186/s10194-018-0890-y
http://link.springer.com/article/10.1186/s10194-018-0890-y
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-10 (2018)
Falkenberg, K, Dunga, B Ó Á, Guo, S, Ashina, M & Olesen, J 2018, ' Cilostazol induced migraine does not respond to sumatriptan in a double blind trial ', The Journal of Headache and Pain, vol. 19, 11 . https://doi.org/10.1186/s10194-018-0841-7
The Journal of Headache and Pain
Falkenberg, K, Dunga, B Ó Á, Guo, S, Ashina, M & Olesen, J 2018, ' Cilostazol induced migraine does not respond to sumatriptan in a double blind trial ', The Journal of Headache and Pain, vol. 19, 11 . https://doi.org/10.1186/s10194-018-0841-7
The Journal of Headache and Pain
Background Cilostazol is an inhibitor of phosphodiesterase 3 and thus causes accumulation of cAMP. It induces migraine-like attacks in migraine patients. Whether the cilostazol model responds to sumatriptan in migraine patients and therefore is valid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0acb1d1c78de9affac3f1ce7c96e1ce3
http://link.springer.com/article/10.1186/s10194-018-0841-7
http://link.springer.com/article/10.1186/s10194-018-0841-7
Autor:
Aleksandr Svistov, YAN CARLOS DUARTE VERA, Lars Kober, Konstantin Ramshev, David Preiss, Miguel Urina, Sotir Marchev, Peter Olexa, Søren Lund Kristensen, Albert HAGEGE, Pardeep Jhund, Mamas Mamas, Ali Vazir, Michel GALINIER, Vladimir Rafalskiy, John Mcmurray, Angus Nightingale, Fernando Lanas, MICHELE SENNI, Jose Silva-Cardoso, Michael Zile, José Albuquerque De Figueiredo Neto, Elena Shutemova, Raj Mohindra, Natalie Bello, Gian Battista Danzi
Publikováno v:
Kristensen, S L, Preiss, D, Jhund, P S, Squire, I, Cardoso, J S, Merkely, B, Martinez, F, Starling, R C, Desai, A S, Lefkowitz, M P, Rizkala, A R, Rouleau, J L, Shi, V C, Solomon, S D, Swedberg, K, Zile, M R, McMurray, J J V, Packer, M & PARADIGM-HF Investigators and Committees 2016, ' Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction : Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial ', Circulation. Heart Failure, vol. 9, no. 1 . https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560
Circulation. Heart Failure
Circulation. Heart failure, 9(1). United States (2016).
Circulation. Heart Failure
Circulation. Heart failure, 9(1). United States (2016).
Background— The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We investigated these in the Prospective Comparison of ARNI With ACEI to Determine Impact on Glob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4175b6b03be4e6fe28284823591aa9db
http://hdl.handle.net/11573/885449
http://hdl.handle.net/11573/885449
Publikováno v:
Bipolar Disorders, Vol. 16, No 6 (2014) pp. 662-666
Lithium is often the mood stabilizer of choice for the treatment of type I bipolar disorder. However, side effects as well as the narrow therapeutic dosing range often complicate its use. Lithium toxicity can be fatal and its serum level needs to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f7ce56cd5a65505a9c6793822a0243
https://doi.org/10.1111/bdi.12174
https://doi.org/10.1111/bdi.12174
Autor:
Aleksandr Svistov, Oksana Drapkina, William Strain, YAN CARLOS DUARTE VERA, Lars Kober, Julio Núñez, Konstantin Ramshev, Manuel Martinez-Selles, Miguel Urina, Thomas Muenzel, Kamal Sharma, Sotir Marchev, MEHMET BIRHAN YILMAZ, Zbigniew Pijanowski, Peter Olexa, Albert HAGEGE, Pardeep Jhund, Mamas Mamas, Jan Krupicka, Marcelo Sanmartin-Fernandez, Michel GALINIER, Vladimir Rafalskiy, John Mcmurray, Roman Libis, Angus Nightingale, Fernando Lanas, MICHELE SENNI, Richard Bogle, Michael Zile, José Albuquerque De Figueiredo Neto, Biykem Bozkurt, Philippe Gosse, Evgeny Zhilyaev, Elena Shutemova, Fernando Manzur, Raj Mohindra, Natalie Bello, Gian Battista Danzi, DİLEK URAL, ROMAN FREIXA-PAMIAS
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
The New England journal of medicine, 371(11), 993-1004. United States (2014).
McMurray, J J V, Packer, M, Desai, A S, Gong, J, Lefkowitz, M P, Rizkala, A R, Rouleau, J L, Shi, V C, Solomon, S D, Swedberg, K, Zile, M R & PARADIGM-HF Investigators and Committees 2014, ' Angiotensin-neprilysin inhibition versus enalapril in heart failure ', The New England Journal of Medicine, vol. 371, no. 11, pp. 993-1004 . https://doi.org/10.1056/NEJMoa1409077
Universidad de Barcelona
The New England journal of medicine, 371(11), 993-1004. United States (2014).
McMurray, J J V, Packer, M, Desai, A S, Gong, J, Lefkowitz, M P, Rizkala, A R, Rouleau, J L, Shi, V C, Solomon, S D, Swedberg, K, Zile, M R & PARADIGM-HF Investigators and Committees 2014, ' Angiotensin-neprilysin inhibition versus enalapril in heart failure ', The New England Journal of Medicine, vol. 371, no. 11, pp. 993-1004 . https://doi.org/10.1056/NEJMoa1409077
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.METHODS: In this double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057eafc951e64542d7bae65b6ab4fe32
http://hdl.handle.net/2445/178508
http://hdl.handle.net/2445/178508
Autor:
Bart Keymeulen, Trevor Orchard, Selcuk Dagdelen, Ivan I. Dedov, Veronique Kerlan, Steve Aldington, Massimo Porta, Ronald Klein, Peter Rossing
Publikováno v:
Sjølie, A K, Klein, R, Porta, M, Orchard, T, Fuller, J, Parving, H H, Bilous, R, Chaturvedi, N & Bek, T 2008, ' Effect of Candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial ', Lancet, vol. 18, no. 372, pp. 1385-93 .
Aarhus University
Sjølie, A K, Klein, R, Porta, M, Orchard, T, Fuller, J, Parving, H H, Bilous, R & Chaturvedi, N 2008, ' Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial ', Lancet, vol. 372, no. 9647, pp. 1385-1393 . https://doi.org/10.1016/S0140-6736(08)61411-7
Aarhus University
Sjølie, A K, Klein, R, Porta, M, Orchard, T, Fuller, J, Parving, H H, Bilous, R & Chaturvedi, N 2008, ' Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial ', Lancet, vol. 372, no. 9647, pp. 1385-1393 . https://doi.org/10.1016/S0140-6736(08)61411-7
Summary Background Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fabf12d349f453d5cd8a4951501f25a
https://doi.org/10.1016/s0140-6736(08)61411-7
https://doi.org/10.1016/s0140-6736(08)61411-7
Autor:
Waeber, B., Ruilope, L.M.
Publikováno v:
Vascular Health and Risk Management, vol. 5, no. 1, pp. 165-174
Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::c3dc762833c4e1991985d02b842d992c
https://serval.unil.ch/notice/serval:BIB_F0D25C6C63EC
https://serval.unil.ch/notice/serval:BIB_F0D25C6C63EC
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.